Serotonin and dopamine interactions in psychosis prevention

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 141-153

  Richtand, Neil M ^a,b   McNamara, Robert K ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

antipsychotic; dopamine; neuroleptic; prevention; prodromal; prodrome; psychosis; schizophrenia; serotonin

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; MESSENGER RNA; OLANZAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ATTENTION; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; DRUG EFFICACY; GENE EXPRESSION; HEALTH PROGRAM; HUMAN; INFORMATION PROCESSING; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; HIPPOCAMPUS; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D3; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 50349096365     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00907-2     Document Type: Review

References (104)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155 6 (1998) 761-767
2. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., and Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1945-1949
3. Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M., Walker E.F., Woods S.W., and Heinssen R. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 33 3 (2007) 665-672
4. Al-Amin H.A., Weinberger D.R., and Lipska B.K. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav. Pharmacol. 11 (2000) 269-278
5. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
6. Betancur C., Lepee-Lorgeoux I., Cazillis M., Accili D., Fuchs S., and Rostene W. Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice. Neuropsychopharmacology 24 2 (2001) 170-182
7. Bogerts B., Lieberman J.A., Ashtari M., Bilder R.M., Degreef G., Lerner G., Johns C., and Masiar S. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol. Psychiatry 33 4 (1993) 236-246
8. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., and Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564 (1991) 203-219
9. Braff D.L., and Freedman R. The Importance of Endophenotypes in Studies of the Genetics of Schizophrenia (2002), Lippincott, Williams and Wilkins, Baltimore, MD
10. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47 (1990) 181-188
11. Braff D.L., Grillon C., and Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49 (1992) 206-215
12. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U.S.A. 94 6 (1997) 2569-2574
13. Cadenhead K.S., Swerdlow N.R., Shafer K.M., Diaz M., and Braff D.L. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am. J. Psychiatry 157 (2000) 1660-1668
14. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2003) 237-260
15. Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., and Sommerville K.W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28 (2003) 182-192
16. Chambers R.A., Moore J., McEvoy J.P., and Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 15 (1996) 587-594
17. Chiang Y.C., Chen P.C., and Chen J.C. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res. 972 (2003) 159-167
18. Chiodo L.A., and Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3 (1983) 1607-1619
19. Cornblatt B.A. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am. J. Med. Genet. 114 (2002) 956-966
20. Cornblatt B.A., Lencz T., and Kane J.M. Treatment of the schizophrenia prodrome: is it presently ethical?. Schizophr. Res. 51 (2001) 31-38
21. Cornblatt B., Lencz T., and Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr. Res. 54 (2002) 177-186
22. Cornblatt B.A., Lencz T., Smith C.W., Olsen R., Auther A.M., Nakayama E., Lesser M.L., Tai J.Y., Shah M.R., Foley C.A., Kane J.M., and Correll C.U. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry 68 4 (2007) 546-557
23. Cornblatt B.A., and Malhotra A.K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am. J. Med. Genet. 105 (2001) 11-15
24. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., and Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 20 (2000) 8677-8684
25. Doherty M.D., and Pickel V.M. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 864 (2000) 176-185
26. Duaux E., Gorwood P., Griffon N., Bourdel M.C., Sautel F., Sokoloff P., Schwartz J.C., Ades J., Loo H., and Poirier M.F. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol. Psychiatry 3 (1998) 333-336
27. Ekman A., Nissbrandt H., Heilig M., Dijkstra D., and Eriksson E. Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn Schmiedebergs Arch. Pharmacol. 358 (1998) 342-350
28. Fletcher R.H., Fletcher S.W., and Wagner E.H. Clinical Epidemiology - The Essentials. 3rd edn. (1966), Williams and Wilkins, Baltimore, MD
29. Flores G., Barbeau D., Quirion R., and Srivastava L.K. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J. Neurosci. 16 (1996) 2020-2026
30. Flores G., Wood G.K., Liang J.J., Quirion R., and Srivastava L.K. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. J. Neurosci. 16 (1996) 7366-7375
31. Glennon R.A., Titeler M., and McKenney J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35 (1984) 2505-2511
32. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003) 636-645
33. Griffon N., Sokoloff P., Diaz J., Levesque D., Sautel F., Schwartz J.C., Simon P., Costentin J., Garrido F., and Mann A. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Eur. Neuropsychopharmacol. 5 Suppl (1995) 3-9
34. Gurevich E.V., and Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20 (1999) 60-80
35. Harvey J.A. Role of the serotonin 5-HT(2A) receptor in learning. Learn. Mem. 10 (2003) 355-362
36. Henry C., Guegant G., Cador M., Arnauld E., Arsaut J., Le Moal M., and Demotes-Mainard J. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens. Brain Res. 685 (1995) 179-186
37. Jay T.M., and Witter M.P. Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgaris-leucoagglutinin. J. Comp. Neurol. 313 (1991) 574-586
38. Khan Z.U., Gutierrez A., Martin R., Penafiel A., Rivera A., and De La Calle A. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J. Comp. Neurol. 402 (1998) 353-371
39. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., and White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18 (1998) 2231-2238
40. Landwehrmeyer B., Mengod G., and Palacios J.M. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5 (1993) 145-153
41. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 800 (1998) 269-274
42. Levesque D., Diaz J., Pilon C., Martres M.P., Giros B., Souil E., Schott D., Morgat J.L., Schwartz J.C., and Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8155-8159
43. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., and Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl.) 112 (1993) S40-S54
44. L'hirondel M., Cheramy A., Godeheu G., Artaud F., Saiardi A., Borrelli E., and Glowinski J. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res. 792 (1998) 253-262
45. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., and Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 44 (1998) 1099-1117
46. Lipska B.K., Al-Amin H.A., and Weinberger D.R. Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage. Neuropsychopharmacology 19 (1998) 451-464
47. Lipska B.K., Jaskiw G.E., and Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9 1 (1993) 67-75
48. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., and Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl.) 122 (1995) 35-43
49. Lipska B.K., and Weinberger D.R. Gonadectomy does not prevent novelty or drug-induced motor hyperresponsiveness in rats with neonatal hippocampal damage. Brain Res. Dev. Brain Res. 78 (1994) 253-258
50. Lipska B.K., and Weinberger D.R. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10 (1994) 199-205
51. Lipska B.K., and Weinberger D.R. Genetic variation in vulnerability to the behavioral effects of neonatal hippocampal damage in rats. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8906-8910
52. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
53. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., Hawkins K.A., Hoffman R.E., Preda A., Epstein I., Addington D., Lindborg S., Trzaskoma Q., Tohen M., and Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163 (2006) 790-799
54. McGorry P.D., Yung A., and Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr. Res. 51 (2001) 17-29
55. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., and Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 59 (2002) 921-928
56. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., and Leysen J.E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl.) 114 (1994) 9-23
57. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) 106S-115S
58. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
59. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
60. Menalled L.B., Dziewczapolski G., Garcia M.C., Rubinstein M., and Gershanik O.S. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. Neuroreport 10 (1999) 3131-3136
61. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci. Biobehav. Rev. 29 (2005) 913-947
62. Moore H., Jentsch J.D., Ghajarnia M., Geyer M.A., and Grace A.A. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol. Psychiatry 60 3 (2006) 253-264
63. Nocjar C., Roth B.L., and Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 111 (2002) 163-176
64. Piercey M.F., Lum J.T., Hoffmann W.E., Carlsson A., Ljung E., and Svensson K. Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232. Brain Res. 588 (1992) 217-222
65. Post R.M., Uhde T.W., Putnam F.W., Ballenger J.C., and Berrettini W.H. Kindling and carbamazepine in affective illness. J. Nerv. Ment. Dis. 170 (1982) 717-731
66. Pritchard L.M., Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., Berger S.P., and Richtand N.M. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 28 (2003) 100-107
67. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., Grewal J.S., and Garnovskaya M.N. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 92 (2001) 179-212
68. Rice D.P. The economic impact of schizophrenia. J. Clin. Psychiatry 60 Suppl 1 (1999) 4-6
69. Richtand N.M. Behavioral sensitization, alternative splicing, and D3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 31 11 (2006) 2368-2375
70. Richtand N.M., Goldsmith R.J., Nolan J.E., and Berger S.P. The D3 dopamine receptor and substance dependence. J. Addict. Dis. 20 (2001) 19-32
71. Richtand N.M., Kelsoe J.R., Segal D.S., and Kuczenski R. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Brain Res. Mol. Brain Res. 33 (1995) 97-103
72. Richtand N.M., Logue A.D., Welge J.A., Perdiue J., Tubbs L.J., Spitzer R.H., Sethuraman G., and Geracioti T.D. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 867 1-2 (2000) 239-242
73. Richtand N.M., Pritchard L.M., and Coolen L.M. Dopamine receptor alternative splicing. In: Schmidt W.J., and Reith M.E.A. (Eds). Dopamine and Glutamate in Psychiatric Disorders (2005), Humana Press, Totowa, NJ 45-61
74. Richtand N.M., Taylor B., Welge J.A., Ahlbrand R., Ostrander M.M., Burr J., Hayes S., Coolen L.M., Pritchard L.M., Logue A., Herman J.P., and McNamara R.K. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 31 1 (2006) 77-89
75. Richtand N.M., Welge J.A., Levant B., Logue A.D., Hayes S., Pritchard L.M., Geracioti T.D., Coolen L.M., and Berger S.P. Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology 28 (2003) 1422-1432
76. Richtand N.M., Woods S.C., Berger S.P., and Strakowski S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev. 25 (2001) 427-443
77. Roth B.L., Hanizavareh S.M., and Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl.) 174 (2004) 17-24
78. Rueter L.E., Ballard M.E., Gallagher K.B., Basso A.M., Curzon P., and Kohlhaas K.L. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl.) 176 (2004) 312-319
79. Sams-Dodd F., Lipska B.K., and Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl.) 132 (1997) 303-310
80. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124 (1996) 57-73
81. Sesack S.R., and Pickel V.M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res. 527 (1990) 266-279
82. Shi L., Fatemi S.H., Sidwell R.W., and Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J. Neurosci. 23 1 (2003) 297-302
83. Sigala S., Missale C., and Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur. J. Pharmacol. 336 (1997) 107-112
84. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
85. Sokoloff P., Martres M.P., Giros B., Bouthenet M.L., and Schwartz J.C. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43 (1992) 659-666
86. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., and Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266 (1993) 684-691
87. Spano P.F., Govoni S., and Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. 19 (1978) 155-165
88. Strange P.G. The structure and mechanism of neurotransmitter receptors. Implications for the structure and function of the central nervous system. Biochem. J. 249 (1988) 309-318
89. Swerdlow N.R., Halim N., Hanlon F.M., Platten A., and Auerbach P.P. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res. Bull. 55 (2001) 71-77
90. Swerdlow N.R., Lipska B.K., Weinberger D.R., Braff D.L., Jaskiw G.E., and Geyer M.A. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology (Berl.) 122 (1995) 27-34
91. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2003) 165-179
92. Ugedo L., Grenhoff J., and Svensson T.H. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl.) 98 (1989) 45-50
93. Varty G.B., Bakshi V.P., and Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20 (1999) 311-321
94. Vogel M., Busse S., Freyberger H.J., and Grabe H.J. Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis. Med. Hypotheses 67 (2006) 354-358
95. Wallace D.R., Mactutus C.F., and Booze R.M. Repeated intravenous cocaine administration: locomotor activity and dopamine D2/D3 receptors. Synapse 23 (1996) 152-163
96. Wan R.Q., and Corbett R. Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. Neuropsychopharmacology 16 (1997) 259-268
97. Wan R.Q., Giovanni A., Kafka S.H., and Corbett R. Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies. Behav. Brain Res. 78 (1996) 211-223
98. Wassef A.A., Dott S.G., Harris A., Brown A., O'Boyle M., Meyer W.J., and Rose R.M. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J. Clin. Psychopharmacol. 19 (1999) 222-232
99. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., and Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural. Transm. Gen. Sect. 94 (1993) 11-19
100. Woods S.W., Breier A., Zipursky R.B., Perkins D.O., Addington J., Miller T.J., Hawkins K.A., Marquez E., Lindborg S.R., Tohen M., and McGlashan T.H. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry 54 (2003) 453-464
101. Xia Z., Gray J.A., Compton-Toth B.A., and Roth B.L. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J. Biol. Chem. 278 (2003) 21901-21908
102. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., White N.M., Graybiel A.M., White F.J., and Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19 (1997) 837-848
103. Zicha J., and Kunes J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol. Rev. 79 (1999) 1227-1282
104. Zuckerman L., Rehavi M., Nachman R., and Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28 (2003) 1778-1789